Obsolete treatments, the lack of an effective vaccine, and the lack of suitable diagnostic tools make it difficult to control the global TB epidemic. Some gains have been made in recent years; the first new TB drugs in half a century and the trial of a shorter course of treatment for drug-resistant TB. But the harsh reality remains - 10 million people fell sick with TB in 2019 and nearly half a million developed drug-resistant TB, which is much harder to treat. The majority go undiagnosed and therefore untreated.
The most widely-used test for diagnosing active TB in developing countries relies on examining a patient’s phlegm under a microscope. This method, developed nearly 140 years ago, detects less than half of all TB cases and largely fails to detect the disease in children and people co-infected with HIV – who usually can’t produce the sputum needed – and those with drug-resistant forms of TB. A diagnostic test, Xpert MTB/RIF, was introduced and we use it in many of our projects, but it can't be used in resource-limited settings.
A course of treatment for uncomplicated TB takes a minimum of six months. Drug-resistant TB (DR-TB) treatment requires taking a cocktail of drugs and can take two years or more, but trials are ongoing to treat it in six to nine months. It is vital that a patient completes their entire course of treatment, even when they start to feel better; incomplete treatment can lead to drug resistance developing. Decentralising treatment by having people cared for at home can help them adhere to treatment and overcome any obstacles they may face.
When patients are resistant to the two most powerful first-line antibiotics (rifampicin and isoniazid), they are considered to have multidrug-resistant TB (MDR-TB). Treatment is long and arduous, with the drugs having many potential side-effects, including psychosis and deafness. People can take as many as 20 pills a day for two years - only to have a cure rate of little better than half. Extensively drug-resistant TB (XDR-TB) occurs when a patient is resistant to second-line drugs. Less than a third of people with XDR-TB are cured.
Most drugs to treat TB are old and toxic. But in the last decade, bedaquiline, delamanid and, more recently, pretomanid, three new TB drugs - the first in half a century - were developed, giving patients hope and treatment providers options. But making these drugs available to patients who desperately need them has been painfully slow. We estimated that, in 2016, only around one in eight people with DR-TB who could have benefited from the lifesaving newer drugs bedaquiline and delamanid were treated with them.
With most of the drugs used to treat TB decades old, some not originally developed for TB use, or having toxic side effects - and treatment itself for DR-TB taking two years - research into new, shorter, more effective drug regimens is urgently needed. MSF is participating in two clinical trials, EndTB and PRACTECAL, to find new treatment regimens. Both trials enrolled their first patients by the end of March 2017.
Sustainable solutions for children and adolescents at risk of drug-resistant tuberculosis
Drug-resistant TB clinical trial ends enrolment early after positive initial data
Step up for TB report 2020
MSF calls on governments and donors to speed up TB testing and treatment
Governments must scale up better TB treatment as J&J drops crucial drug price
MSF opens field hospital as South Africa braces for COVID-19
Eswatini: Responding to COVID-19 in a country already fighting a dual HIV/TB epidemic
Between war and fragile health systems, tackling TB in Sudan and South Sudan
COVID-19: Avoiding a ‘second tragedy’ for those with TB
MSF Tuberculosis Researchfieldresearch.msf.org
We produce important research based on our field experience. So far, we have published articles in over 100 peer-reviewed journals. These articles have often changed clinical practice and have been used for humanitarian advocacy. Read all our Tuberculosis-related articles on our dedicated Field Research website.